Discovery of antibody biomarkers for Alzheimer’s Disease

 描述(由申请人提供)：阿尔茨海默病(AD)血清生物标记物的发现代表着巨大的未得到满足的医疗需求。该项目将进一步探索这样的假设，即适应性免疫系统可能会对AD病理产生的不寻常抗原产生反应，从而产生正常个体中不存在的高水平抗体。有一些证据表明情况就是这样。为了发现这些抗体，我们计划筛选大量珠状显示的合成寡聚体，并发现从AD血清样本中保留的抗体比来自对照组的抗体要多得多的化合物。这些分子将被用作第一代AD特异性抗体的“捕获剂”，用于多路Luminex类诊断试验。如果R21的初步研究成功，它将为化合物优化和更大规模的验证试验奠定基础，从而可能导致有效的AD血液测试。

 DESCRIPTION (provided by applicant): The discovery of serum biomarkers for Alzheimer's disease (AD) represents an enormous unmet medical need. This project will further explore the hypothesis that the adaptive immune system might react to unusual antigens produced as a result of AD pathology and as a result produce high levels of antibodies that would not be found in a normal individual. There is some evidence that this is the case. To discover these antibodies we plan to screen large libraries of bead-displayed synthetic oligomers and find compounds that retain far more antibodies from AD serum samples than from controls. These molecules would be employed as first generation "capture agents" for the AD-specific antibodies in a multiplexed Luminex-like diagnostic assay. If this R21 preliminary investigation is successful, it would set the stage for compound optimization and a much larger validation trial that could lead to an effective blood test for AD.